We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Optibiotix Health Plc | LSE:OPTI | London | Ordinary Share | GB00BP0RTP38 | ORD 2P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 18.00 | 17.50 | 18.50 | 18.00 | 18.00 | 18.00 | 66,018 | 08:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Noncomml Resh Organizations | 457k | 2.59M | 0.0284 | 6.34 | 16.41M |
Date | Subject | Author | Discuss |
---|---|---|---|
31/8/2018 08:08 | Onto a twig? | rayrac | |
31/8/2018 07:52 | Keep holding. | ken chung | |
31/8/2018 07:40 | I think you need to look at the cashflow statement and balance sheet. What's the available cash on the balance sheet? How much did they raise? How much did they use in operating activities? Do keep up. | michaelmouse | |
30/8/2018 23:09 | Cyberbub, i think elrico suggested around £12 million by the end of 2020. Didn't TW quote this figure in one of his updates earlier this year? Maybe i'm remembering it wrong. | incanus | |
30/8/2018 22:17 | To reach 250p (=£200M cap) on a rapid growth p/e of 40 needs just £5M net profits. With the low M&A, and high-margin sales that usually come from licensing deals, I would suggest around £8M in revenue is required. Given the size of the partners involved in the company's recent announcements, I don't think it will be difficult to reach £8M revenue. Maybe not tomorrow, but soon enough for people willing to be patient.NAI | cyberbub | |
30/8/2018 22:16 | Cash burn is not over £1m though is it. £300k is the 41.9% of SKINBIO cash burn which has no impact on Optis cash reserves. Do keep up | riskybusiness1 | |
30/8/2018 21:58 | Rampers are a little touchy this evening. | monkeywench1 | |
30/8/2018 21:51 | monkey your a right charlie | manc10 | |
30/8/2018 21:30 | I’m sure the dog above me is barking something about Elrico. Shows the obsession some people have with him. They probably need to get laid. | loungeact | |
30/8/2018 21:18 | But elrampo has allowed me to join the forum! Not very robust is he!! OH the joy of him trying to work out who i am. | monkeywench1 | |
30/8/2018 20:33 | The one where Elrico has sole discretion to let you join or not. | imnotlong | |
30/8/2018 20:21 | What private forum? | slartybartfaster | |
30/8/2018 19:32 | I’ve not seen that expectation of an exciting September and October comment Slarty. Is that from the private forum? | imnotlong | |
30/8/2018 18:56 | Is anyone having trouble posting on the lemming blog? | slartybartfaster | |
30/8/2018 18:52 | If the expectation of an exciting september and october is anything to go by, then its weeks and months. | slartybartfaster | |
30/8/2018 18:48 | KMANN is so super smart, he confuses a meal replacement shake with a empty calorific kitkat. No hope. Best join a paid for research site, if that is the level of research. | slartybartfaster | |
30/8/2018 18:44 | Cheers Parob. Let’s hope the newsflow materialises. I noticed the language from SoH has changed from Elrico’s blog when he said ‘news in the next few days, weeks & months’ to ‘months and years’ in today’s RNS. I believe short term expectations had been raised and not delivered upon. Not that my view has any bearing on anything, unlike the great KMann with his thousands of followers that listen to his every word. | imnotlong | |
30/8/2018 18:05 | Yes still targeting £2-2.50+ by year end based on regular news flow and frequent deal announcements over the next four months. The interims didn't surprise me massively - I don't see an income lag. It is all about future hockey-style revenue growth for me, plus any bio therapeutic deals will give the shares a real boost. | parob |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions